2. Academic Validation
  3. STK899704 inhibits stemness of cancer stem cells and migration via the FAK-MEK-ERK pathway in HT29 cells

STK899704 inhibits stemness of cancer stem cells and migration via the FAK-MEK-ERK pathway in HT29 cells

  • BMB Rep. 2018 Nov;51(11):596-601. doi: 10.5483/BMBRep.2018.51.11.180.
Hui-Ju Jang 1,  Yesol Bak 1,  Thu-Huyen Pham 1,  Sae-Bom Kwon 1,  Bo-Yeon Kim 2,  JinTae Hong 3,  Do-Young Yoon 1
Affiliations

Affiliations

  • 1 Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Korea.
  • 2 World Class Institute, Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology, Chungbuk 28116, Korea.
  • 3 College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju 28160, Korea.
PMID: 30269740 DOI: 10.5483/BMBRep.2018.51.11.180
Abstract

Colon Cancer is one of the most lethal and common malignancies worldwide. STK899704, a novel synthetic agent, has been reported to exhibit Anticancer effects towards numerous Cancer cells. However, the effect of STK899704 on the biological properties of colon Cancer, including Cancer cell migration and Cancer Stem Cells (CSCs), remains unknown. Here, we examined the inhibitory effect of STK899704 on cell migration and CSC stemness. In the wound healing assay, STK899704 significantly inhibited the motility of colon Cancer cells. Furthermore, STK899704 downregulated the mRNA expression levels of the cell migration mediator focal adhesion kinase (FAK). STK899704 also suppressed mitogen-activated protein kinase kinase and extracellular signal-regulated kinase, which are downstream signaling molecules of FAK. Additionally, STK899704 inhibited stemness gene expression and sphere formation in colon Cancer Stem Cells. These results suggest that STK899704 can be used to treat human colon Cancer. [BMB Reports 2018; 51(11): 596-601].

Figures
Products